Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 140 articles: HTML format

Single Articles

March 2023
1. PLICHTA JK, Thomas SM, Hayes DF, Chavez-MacGregor M, et al
   Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
   J Clin Oncol. 2023 Mar 21:JCO2202222. doi: 10.1200/JCO.22.02222.
   PubMed     Abstract available
   
   
   
2. VOGEL CL, Cobleigh MA, Tripathy D, Gutheil JC, et al
   Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
   J Clin Oncol. 2023;41:1638-1645.
   PubMed     Abstract available
   
   
   
3. 
   JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002).
   J Clin Oncol. 2023;41:1637.
   PubMed    
   
   
   
4. GRIGGS JJ
   Flashback Foreword: Activity of First-Line Trastuzumab.
   J Clin Oncol. 2023;41:1635-1636.
   PubMed    
   
   
   
5. ERIKSSON M, Czene K, Vachon C, Conant EF, et al
   Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer.
   J Clin Oncol. 2023 Mar 17:JCO2201564. doi: 10.1200/JCO.22.01564.
   PubMed     Abstract available
   
   
   
6. COBLEIGH MA, Vogel CL, Tripathy D, Robert NJ, et al
   Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
   J Clin Oncol. 2023;41:1501-1510.
   PubMed     Abstract available
   
   
   
7. HARVEY JM, Clark GM, Osborne CK, Allred DC, et al
   Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer.
   J Clin Oncol. 2023;41:1331-1338.
   PubMed     Abstract available
   
   
   
8. GANZ PA
   Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer.
   J Clin Oncol. 2023;41:1329-1330.
   PubMed    
   
   
   February 2023
9. HARBECK N, Nitz UA, Christgen M, Kummel S, et al
   De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
   J Clin Oncol. 2023 Feb 21:JCO2201816. doi: 10.1200/JCO.22.01816.
   PubMed     Abstract available
   
   
   
10. NARAYAN P, Dilawari A, Osgood C, Feng Z, et al
    US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
    J Clin Oncol. 2023 Feb 13:JCO2202447. doi: 10.1200/JCO.22.02447.
    PubMed     Abstract available
    
    
    
11. YANG S, Tan M, Gao F, Xu X, et al
    Cognitive Problems in Older Breast Cancer Survivors.
    J Clin Oncol. 2023 Feb 13:JCO2202282. doi: 10.1200/JCO.22.02282.
    PubMed    
    
    
    January 2023
12. TAGLIAMENTO M, Gennari A, Lambertini M, Salazar R, et al
    Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.
    J Clin Oncol. 2023 Jan 31:JCO2201667. doi: 10.1200/JCO.22.01667.
    PubMed     Abstract available
    
    
    
13. TRAPANI D
    Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
    J Clin Oncol. 2023 Jan 30:JCO2202477. doi: 10.1200/JCO.22.02477.
    PubMed     Abstract available
    
    
    
14. LEVASSEUR N, Gelmon KA
    Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care.
    J Clin Oncol. 2023 Jan 26:JCO2202863. doi: 10.1200/JCO.22.02863.
    PubMed    
    
    
    
15. LOPES CARDOZO JMN, Andrulis IL, Bojesen SE, Dork T, et al
    Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
    J Clin Oncol. 2023 Jan 23:JCO2201978. doi: 10.1200/JCO.22.01978.
    PubMed     Abstract available
    
    
    
16. HERSHMAN DL, Bansal A, Sullivan SD, Barlow WE, et al
    A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
    J Clin Oncol. 2023;41:590-598.
    PubMed     Abstract available
    
    
    
17. KONSTANTINOPOULOS PA, Lee EK, Xiong N, Krasner C, et al
    A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
    J Clin Oncol. 2023;41:599-608.
    PubMed     Abstract available
    
    
    
18. MOY B, Rumble RB, Carey LA
    Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Jan 10:JCO2202807. doi: 10.1200/JCO.22.02807.
    PubMed     Abstract available
    
    
    
19. YADAV S, Boddicker NJ, Na J, Polley EC, et al
    Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
    J Clin Oncol. 2023 Jan 9:JCO2201239. doi: 10.1200/JCO.22.01239.
    PubMed     Abstract available
    
    
    
20. SG N, Gogia A
    Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2023 Jan 6:JCO2202113. doi: 10.1200/JCO.22.02113.
    PubMed    
    
    
    
21. NATTINGER AB, Bickell NA, Schymura MJ, Laud P, et al
    Centralization of Initial Care and Improved Survival of Poor Patients With Breast Cancer.
    J Clin Oncol. 2023 Jan 5:JCO2202012. doi: 10.1200/JCO.22.02012.
    PubMed     Abstract available
    
    
    
22. SJOSTROM M, Fyles A, Liu FF, McCready D, et al
    Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2023 Jan 4:JCO2200655. doi: 10.1200/JCO.22.00655.
    PubMed     Abstract available
    
    
    December 2022
23. NAOUM GE, Taghian AG
    Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right?
    J Clin Oncol. 2022 Dec 20:JCO2202171. doi: 10.1200/JCO.22.02171.
    PubMed    
    
    
    
24. NISHIHARA R, Shimomura A, Shimizu C
    Oral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor.
    J Clin Oncol. 2022;40:4280-4281.
    PubMed    
    
    
    
25. CONNOLLY RM, Miller KD
    Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women.
    J Clin Oncol. 2022 Dec 15:JCO2202319. doi: 10.1200/JCO.22.02319.
    PubMed    
    
    
    
26. PAGANI O, Walley BA, Fleming GF, Colleoni M, et al
    Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
    J Clin Oncol. 2022 Dec 15:JCO2201064. doi: 10.1200/JCO.22.01064.
    PubMed     Abstract available
    
    
    
27. FRANCIS PA, Fleming GF, Lang I, Ciruelos EM, et al
    Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    J Clin Oncol. 2022 Dec 9:JCO2201065. doi: 10.1200/JCO.22.01065.
    PubMed     Abstract available
    
    
    
28. BEHROOZIAN T, Milton L, Karam I, Zhang L, et al
    Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial.
    J Clin Oncol. 2022 Dec 9:JCO2201873. doi: 10.1200/JCO.22.01873.
    PubMed     Abstract available
    
    
    
29. SUN J, Chu F, Pan J, Zhang Y, et al
    BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
    J Clin Oncol. 2022 Dec 8:JCO2200833. doi: 10.1200/JCO.22.00833.
    PubMed     Abstract available
    
    
    
30. SEDRAK MS, Sun CL, Ji J, Cohen HJ, et al
    Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.
    J Clin Oncol. 2022 Dec 1:JCO2201440. doi: 10.1200/JCO.22.01440.
    PubMed     Abstract available
    
    
    
31. JAYASEKERA J, Zhao A, Schechter C, Lowry K, et al
    Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Dec 1:JCO2201342. doi: 10.1200/JCO.22.01342.
    PubMed     Abstract available
    
    
    November 2022
32. SANTA-MARIA CA, Wolff AC
    Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets.
    J Clin Oncol. 2022 Nov 29:JCO2202217. doi: 10.1200/JCO.22.02217.
    PubMed    
    
    
    
33. BARTELS SAL, Donker M, Poncet C, Sauve N, et al
    Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
    J Clin Oncol. 2022 Nov 16:JCO2201565. doi: 10.1200/JCO.22.01565.
    PubMed     Abstract available
    
    
    
34. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
    FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
    J Clin Oncol. 2022;40:3750-3761.
    PubMed     Abstract available
    
    
    
35. RUGO HS, Im SA, Cardoso F, Cortes J, et al
    Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
    J Clin Oncol. 2022 Nov 4:JCO2102937. doi: 10.1200/JCO.21.02937.
    PubMed     Abstract available
    
    
    
36. MORAN MS, Ho AY
    Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?
    J Clin Oncol. 2022 Nov 4:JCO2201751. doi: 10.1200/JCO.22.01751.
    PubMed     Abstract available
    
    
    
37. MCCAW ZR, Ludmir EB, Wei LJ
    Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    J Clin Oncol. 2022 Nov 3:JCO2201759. doi: 10.1200/JCO.22.01759.
    PubMed    
    
    
    
38. AKECHI T, Yamaguchi T, Uchida M, Imai F, et al
    Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study).
    J Clin Oncol. 2022 Nov 2:JCO2200699. doi: 10.1200/JCO.22.00699.
    PubMed     Abstract available
    
    
    
39. HINDIE E, Groheux D
    Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help.
    J Clin Oncol. 2022;40:3669-3670.
    PubMed    
    
    
    
40. GAIL MH, Jatoi I
    Tools for Contralateral Prophylactic Mastectomy Decision Making.
    J Clin Oncol. 2022;40:3653-3659.
    PubMed     Abstract available
    
    
    October 2022
41. EVRON E, Ben-David MA, Kaidar-Person O, Corn BW, et al
    Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609.
    PubMed    
    
    
    
42. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
    Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
    PubMed     Abstract available
    
    
    
43. SANCHEZ KG, Nangia JR, Schiff R, Rimawi MF, et al
    Elacestrant and the Promise of Oral SERDs.
    J Clin Oncol. 2022;40:3227-3229.
    PubMed    
    
    
    September 2022
44. CARROLL JE, Nakamura ZM, Small BJ, Zhou X, et al
    Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
    J Clin Oncol. 2022 Sep 30:JCO2200406. doi: 10.1200/JCO.22.00406.
    PubMed     Abstract available
    
    
    
45. JI J, Sun CL, Cohen HJ, Synold T, et al
    Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
    J Clin Oncol. 2022 Sep 20:JCO2201217. doi: 10.1200/JCO.22.01217.
    PubMed     Abstract available
    
    
    
46. LV M, Luo X, Chen Y
    Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology.
    J Clin Oncol. 2022 Sep 19:JCO2201061. doi: 10.1200/JCO.22.01061.
    PubMed    
    
    
    
47. WHEELER SB, Rotter J, Gogate A, Reeder-Hayes KE, et al
    Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
    J Clin Oncol. 2022 Sep 2:JCO2102473. doi: 10.1200/JCO.21.02473.
    PubMed     Abstract available
    
    
    August 2022
48. MANKOFF DA, Clark AS, Edmonds CE, O'Brien SR, et al
    16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography to Measure Regional Estrogen Receptor Expression in Breast Cancer.
    J Clin Oncol. 2022 Aug 30:JCO2201055. doi: 10.1200/JCO.22.01055.
    PubMed    
    
    
    
49. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2201002. doi: 10.1200/JCO.22.01002.
    PubMed     Abstract available
    
    
    
50. DAVIDSON NE
    In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Aug 26:JCO2201465. doi: 10.1200/JCO.22.01465.
    PubMed    
    
    
    
51. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
    Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial.
    J Clin Oncol. 2022 Aug 5:JCO2200451. doi: 10.1200/JCO.22.00451.
    PubMed     Abstract available
    
    
    
52. MOY B, Rumble RB, Carey LA
    Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Aug 4:JCO2201533. doi: 10.1200/JCO.22.01533.
    PubMed     Abstract available
    
    
    July 2022
53. JOHANSSON A, Dar H, van 't Veer LJ, Tobin NP, et al
    Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    J Clin Oncol. 2022 Jul 21:JCO2102844. doi: 10.1200/JCO.21.02844.
    PubMed     Abstract available
    
    
    
54. RUGO HS, Umanzor GA, Barrios FJ, Vasallo RH, et al
    Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
    J Clin Oncol. 2022 Jul 20:JCO2102953. doi: 10.1200/JCO.21.02953.
    PubMed     Abstract available
    
    
    
55. ULAS KAHYA B, Sutcuoglu O, Yazici O, Ozdemir N, et al
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol. 2022 Jul 12:JCO2200404. doi: 10.1200/JCO.22.00404.
    PubMed    
    
    
    
56. SORAN A, Aytac O, Ozbas S
    Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer.
    J Clin Oncol. 2022 Jul 12:JCO2200802. doi: 10.1200/JCO.22.00802.
    PubMed    
    
    
    
57. LU Y, Meng D, Hui B, Yuan W, et al
    The Deep Inspiration Breath-Hold Technique May Be a Win-Win Option for the Treatment of Patients in Node-Positive Early Left-Sided Breast Cancer.
    J Clin Oncol. 2022 Jul 5:JCO2200931. doi: 10.1200/JCO.22.00931.
    PubMed    
    
    
    June 2022
58. COBAIN EF, Hayes DF
    Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 29:JCO2200702. doi: 10.1200/JCO.22.00702.
    PubMed    
    
    
    
59. HUOBER J, Barrios CH, Niikura N, Jarzab M, et al
    Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
    J Clin Oncol. 2022 Jun 28:JCO2102772. doi: 10.1200/JCO.21.02772.
    PubMed     Abstract available
    
    
    
60. HENRY NL, Somerfield MR, Dayao Z, Elias A, et al
    Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Jun 27:JCO2201063. doi: 10.1200/JCO.22.01063.
    PubMed     Abstract available
    
    
    
61. CHEN YJ, Yeh MH, Wei JC
    Considerations of Subgroup Classification When Analyzing Risk of Developing Cardiometabolic Risk Factors in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200416. doi: 10.1200/JCO.22.00416.
    PubMed    
    
    
    
62. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    
    
    
    
63. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available
    
    
    
64. REDING KW, Cheng RK, Barac A, Vasbinder A, et al
    Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer.
    J Clin Oncol. 2022 Jun 10:JCO2200111. doi: 10.1200/JCO.22.00111.
    PubMed    
    
    
    
65. MITTENDORF EA, King TA, Tolaney SM
    Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 8:JCO2200173. doi: 10.1200/JCO.22.00173.
    PubMed    
    
    
    
66. CESCON DW, Kalinsky K, DeMichele AM
    Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
    J Clin Oncol. 2022 Jun 4:JCO2201026. doi: 10.1200/JCO.22.01026.
    PubMed    
    
    
    
67. LIPSYC-SHARF M, de Bruin EC, Santos K, McEwen R, et al
    Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO.22.00908.
    PubMed     Abstract available
    
    
    
68. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available
    
    
    
69. ZACHARAKIS N, Huq LM, Seitter SJ, Kim SP, et al
    Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
    J Clin Oncol. 2022;40:1741-1754.
    PubMed     Abstract available
    
    
    May 2022
70. GIORDANO SH, Franzoi MAB, Temin S, Anders CK, et al
    Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200519. doi: 10.1200/JCO.22.00519.
    PubMed     Abstract available
    
    
    
71. RAMAKRISHNA N, Anders CK, Lin NU, Morikawa A, et al
    Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200520. doi: 10.1200/JCO.22.00520.
    PubMed     Abstract available
    
    
    
72. BACHELOT T, Cottu P, Chabaud S, Dalenc F, et al
    Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    J Clin Oncol. 2022 May 23:JCO2102179. doi: 10.1200/JCO.21.02179.
    PubMed     Abstract available
    
    
    
73. VAN GEEL JJL, Boers J, Elias SG, Glaudemans AWJM, et al
    Clinical Validity of 16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
    J Clin Oncol. 2022 May 18:JCO2200400. doi: 10.1200/JCO.22.00400.
    PubMed     Abstract available
    
    
    
74. BIDARD FC, Kaklamani VG, Neven P, Streich G, et al
    Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
    J Clin Oncol. 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338.
    PubMed     Abstract available
    
    
    
75. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    
    
    
    
76. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    
    
    
    
77. DAMODARAN S, Zhao F, Deming DA, Mitchell EP, et al
    Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    J Clin Oncol. 2022;40:1552-1561.
    PubMed     Abstract available
    
    
    
78. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available
    
    
    
79. SINGLETON AC, Raeside R, Hyun KK, Partridge SR, et al
    Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses.
    J Clin Oncol. 2022 May 2:JCO2101171. doi: 10.1200/JCO.21.01171.
    PubMed     Abstract available
    
    
    April 2022
80. JIN Z, Zhang S, Zhang L, Chen Q, et al
    Artificial Intelligence Risk Model (Mirai) Delivers Robust Generalization and Outperforms Tyrer-Cuzick Guidelines in Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102908. doi: 10.1200/JCO.21.02908.
    PubMed    
    
    
    
81. ERIKSSON M, Conant EF, Kontos D, Hall P, et al
    Risk Assessment in Population-Based Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102827. doi: 10.1200/JCO.21.02827.
    PubMed    
    
    
    
82. DI MEGLIO A, Havas J, Gbenou AS, Martin E, et al
    Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
    J Clin Oncol. 2022 Apr 21:JCO2100277. doi: 10.1200/JCO.21.00277.
    PubMed     Abstract available
    
    
    
83. VLIEK SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, et al
    Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
    J Clin Oncol. 2022 Apr 20:JCO2100311. doi: 10.1200/JCO.21.00311.
    PubMed     Abstract available
    
    
    
84. LOPES CARDOZO JMN, Drukker CA, Rutgers EJT, Schmidt MK, et al
    Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    J Clin Oncol. 2022;40:1335-1345.
    PubMed     Abstract available
    
    
    
85. BEAVIS PA, Derrick EB, Loi S
    Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.
    J Clin Oncol. 2022 Apr 19:JCO2200284. doi: 10.1200/JCO.22.00284.
    PubMed    
    
    
    
86. BRAUER ER, Ganz PA
    Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice.
    J Clin Oncol. 2022 Apr 19:JCO2200174. doi: 10.1200/JCO.22.00174.
    PubMed    
    
    
    
87. ANDRE F, Ismaila N, Allison KH, Barlow WE, et al
    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Apr 19:JCO2200069. doi: 10.1200/JCO.22.00069.
    PubMed     Abstract available
    
    
    
88. ASAZUMA K, Shimomura A, Shimizu C
    Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200135. doi: 10.1200/JCO.22.00135.
    PubMed    
    
    
    
89. KORDE LA, Somerfield MR, Hershman DL
    Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Apr 13:JCO2200503. doi: 10.1200/JCO.22.00503.
    PubMed     Abstract available
    
    
    
90. DOWSETT M
    Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Apr 12:JCO2200214. doi: 10.1200/JCO.22.00214.
    PubMed    
    
    
    
91. NITZ UA, Gluz O, Kummel S, Christgen M, et al
    Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
    J Clin Oncol. 2022 Apr 11:JCO2102759. doi: 10.1200/JCO.21.02759.
    PubMed     Abstract available
    
    
    
92. THORSEN LBJ, Overgaard J, Matthiessen LW, Berg M, et al
    Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study.
    J Clin Oncol. 2022 Apr 8:JCO2200044. doi: 10.1200/JCO.22.00044.
    PubMed     Abstract available
    
    
    
93. GREENLEE H, Iribarren C, Rana JS, Cheng R, et al
    Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Apr 6:JCO2101736. doi: 10.1200/JCO.21.01736.
    PubMed     Abstract available
    
    
    March 2022
94. NOZAWA K, Hattori M, Yoshimura A, Iwata H, et al
    Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?
    J Clin Oncol. 2022 Mar 31:JCO2200153. doi: 10.1200/JCO.22.00153.
    PubMed    
    
    
    
95. DE JONG VMT, Wang Y, Ter Hoeve ND, Opdam M, et al
    Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    J Clin Oncol. 2022 Mar 30:JCO2101536. doi: 10.1200/JCO.21.01536.
    PubMed     Abstract available
    
    
    
96. QIN B, Kim K, Goldman N, Rundle AG, et al
    Multilevel Factors for Adiposity Change in a Population-Based Prospective Study of Black Breast Cancer Survivors.
    J Clin Oncol. 2022 Mar 25:JCO2102973. doi: 10.1200/JCO.21.02973.
    PubMed     Abstract available
    
    
    
97. VAZ-LUIS I, Di Meglio A, Havas J, El-Mouhebb M, et al
    Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
    J Clin Oncol. 2022 Mar 15:JCO2101958. doi: 10.1200/JCO.21.01958.
    PubMed     Abstract available
    
    
    
98. SALERNO EA, Culakova E, Heckler CE, Janelsins MC, et al
    Reply to S. Ning et al.
    J Clin Oncol. 2022;40:916-918.
    PubMed    
    
    
    
99. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available
    
    
    
100. JATOI I
     Ductal Carcinoma In Situ and Breast Cancer Overdiagnosis.
     J Clin Oncol. 2022 Mar 4:JCO2102802. doi: 10.1200/JCO.21.02802.
     PubMed    
     
     
     
101. GRIMM LJ, Plichta JK, Hwang ES
     More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk.
     J Clin Oncol. 2022 Mar 4:JCO2102733. doi: 10.1200/JCO.21.02733.
     PubMed    
     
     
     
102. THOMAS A, Parsons HA, Smith KL
     Late Recurrence Following Early Breast Cancer.
     J Clin Oncol. 2022 Mar 3:JCO2200167. doi: 10.1200/JCO.22.00167.
     PubMed     Abstract available
     
     
     February 2022
103. JAHAN N, Cathcart-Rake EJ, Ruddy KJ
     Late Breast Cancer Survivorship: Side Effects and Care Recommendations.
     J Clin Oncol. 2022 Feb 28:JCO2200049. doi: 10.1200/JCO.22.00049.
     PubMed     Abstract available
     
     
     
104. HICKS D, O'Regan RM
     Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
     J Clin Oncol. 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.
     PubMed     Abstract available
     
     
     
105. KEMP EB, Geerse OP, Knowles R, Woodman R, et al
     Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis.
     J Clin Oncol. 2022 Feb 16:JCO2102015. doi: 10.1200/JCO.21.02015.
     PubMed     Abstract available
     
     
     
106. PEDERSEN RN, Mellemkjaer L, Ejlertsen B, Norgaard M, et al
     Mortality After Late Breast Cancer Recurrence in Denmark.
     J Clin Oncol. 2022 Feb 16:JCO2102062. doi: 10.1200/JCO.21.02062.
     PubMed     Abstract available
     
     
     
107. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
     Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
     J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
     PubMed     Abstract available
     
     
     
108. ANDERSON DN, Port ER
     Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.
     J Clin Oncol. 2022 Feb 4:JCO2102706. doi: 10.1200/JCO.21.02706.
     PubMed     Abstract available
     
     
     
109. PARAMANANDAM VS, Dylke E, Clark GM, Daptardar AA, et al
     Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
     J Clin Oncol. 2022 Feb 2:JCO2102567. doi: 10.1200/JCO.21.02567.
     PubMed     Abstract available
     
     
     
110. PFOB A, Sidey-Gibbons C, Rauch G, Thomas B, et al
     Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
     J Clin Oncol. 2022 Feb 2:JCO2102439. doi: 10.1200/JCO.21.02439.
     PubMed     Abstract available
     
     
     
111. CARLOS RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, et al
     Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach.
     J Clin Oncol. 2022 Feb 2:JCO2102004. doi: 10.1200/JCO.21.02004.
     PubMed    
     
     
     
112. BARTON DL, Pugh SL, Ganz PA, Plaxe SC, et al
     Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
     J Clin Oncol. 2022;40:324-334.
     PubMed     Abstract available
     
     
     January 2022
113. ROYCE M, Osgood C, Mulkey F, Bloomquist E, et al
     FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
     J Clin Oncol. 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.
     PubMed     Abstract available
     
     
     
114. RAFN BS, Christensen J, Larsen A, Bloomquist K, et al
     Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2022 Jan 25:JCO2101681. doi: 10.1200/JCO.21.01681.
     PubMed     Abstract available
     
     
     
115. DI MEGLIO A, Havas J, Soldato D, Presti D, et al
     Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
     J Clin Oncol. 2022 Jan 21:JCO2101252. doi: 10.1200/JCO.21.01252.
     PubMed     Abstract available
     
     
     
116. NING S, Qiao K, Pan L
     Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer.
     J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073.
     PubMed    
     
     
     
117. WRIGHT JL, Rahbar H, Obeng-Gyasi S, Carlos R, et al
     Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
     J Clin Oncol. 2022;40:225-230.
     PubMed    
     
     
     
118. SHEPHERD JH, Ballman K, Polley MC, Campbell JD, et al
     CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
     J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506.
     PubMed     Abstract available
     
     
     
119. EISEN A, Somerfield MR, Accordino MK, Blanchette PS, et al
     Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
     J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647.
     PubMed     Abstract available
     
     
     
120. KWAN ML, Cheng RK, Iribarren C, Neugebauer R, et al
     Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
     J Clin Oncol. 2022 Jan 13:JCO2101738. doi: 10.1200/JCO.21.01738.
     PubMed     Abstract available
     
     
     
121. JOENSUU H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, et al
     Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
     J Clin Oncol. 2022 Jan 12:JCO2102054. doi: 10.1200/JCO.21.02054.
     PubMed     Abstract available
     
     
     
122. KHAN SA, Zhao F, Goldstein LJ, Cella D, et al
     Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
     J Clin Oncol. 2022 Jan 7:JCO2102006. doi: 10.1200/JCO.21.02006.
     PubMed     Abstract available
     
     
     
123. MAYER EL, Fesl C, Hlauschek D, Garcia-Estevez L, et al
     Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/AB
     J Clin Oncol. 2022 Jan 7:JCO2101918. doi: 10.1200/JCO.21.01918.
     PubMed     Abstract available
     
     
     December 2021
124. SCHNEIDER BP, Jiang G, Ballinger TJ, Shen F, et al
     BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
     J Clin Oncol. 2021 Dec 15:JCO2101657. doi: 10.1200/JCO.21.01657.
     PubMed     Abstract available
     
     
     
125. KROP IE, Im SA, Barrios C, Bonnefoi H, et al
     Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
     J Clin Oncol. 2021 Dec 10:JCO2100896. doi: 10.1200/JCO.21.00896.
     PubMed     Abstract available
     
     
     
126. YADAV S, Hu C, Nathanson KL, Weitzel JN, et al
     Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
     J Clin Oncol. 2021;39:3918-3926.
     PubMed     Abstract available
     
     
     
127. GIORDANO SH, Freedman RA, Somerfield MR
     Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
     J Clin Oncol. 2021 Dec 8:JCO2102677. doi: 10.1200/JCO.21.02677.
     PubMed     Abstract available
     
     
     
128. GNANT M, Dueck AC, Frantal S, Martin M, et al
     Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
     J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554.
     PubMed     Abstract available
     
     
     November 2021
129. YALA A, Mikhael PG, Strand F, Lin G, et al
     Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
     J Clin Oncol. 2021 Nov 12:JCO2101337. doi: 10.1200/JCO.21.01337.
     PubMed     Abstract available
     
     
     
130. WARREN LEG, Bellon JR
     Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
     J Clin Oncol. 2021;39:3535-3540.
     PubMed     Abstract available
     
     
     
131. MCCORMICK B, Winter KA, Woodward W, Kuerer HM, et al
     Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
     J Clin Oncol. 2021;39:3574-3582.
     PubMed     Abstract available
     
     
     October 2021
132. BORGES VF
     Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
     J Clin Oncol. 2021 Oct 28:JCO2101910. doi: 10.1200/JCO.21.01910.
     PubMed     Abstract available
     
     
     
133. ADEMUYIWA FO, Salyer P, Tao Y, Luo J, et al
     Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
     J Clin Oncol. 2021 Oct 18:JCO2101426. doi: 10.1200/JCO.21.01426.
     PubMed     Abstract available
     
     
     
134. PALMER JR, Zirpoli G, Bertrand KA, Battaglia T, et al
     A Validated Risk Prediction Model for Breast Cancer in US Black Women.
     J Clin Oncol. 2021 Oct 8:JCO2101236. doi: 10.1200/JCO.21.01236.
     PubMed     Abstract available
     
     
     September 2021
135. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
     Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
     J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
     PubMed     Abstract available
     
     
     
136. JAYASEKERA J, Sparano JA, O'Neill S, Chandler Y, et al
     Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
     J Clin Oncol. 2021;39:2893-2902.
     PubMed     Abstract available
     
     
     July 2021
137. COBLEIGH MA, Anderson SJ, Siziopikou KP, Arthur DW, et al
     Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
     J Clin Oncol. 2021;39:2367-2374.
     PubMed     Abstract available
     
     
     June 2021
138. TURAN V, Lambertini M, Lee DY, Wang E, et al
     Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
     J Clin Oncol. 2021;39:2016-2024.
     PubMed     Abstract available
     
     
     
139. ERIKSSON M, Eklund M, Borgquist S, Hellgren R, et al
     Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
     J Clin Oncol. 2021;39:1899-1908.
     PubMed     Abstract available
     
     
     May 2021
140. PRAT A, Chaudhury A, Solovieff N, Pare L, et al
     Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
     J Clin Oncol. 2021;39:1458-1467.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: